Beyond upregulation of other anti-apoptotic Bcl-2-family members that are not inhibited by venetoclax, Bcl-2 mutations have emerged in CLL patients undergoing venetoclax treatment. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.